Status:
COMPLETED
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib
Lead Sponsor:
National University Hospital, Singapore
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
We hypothesize that Epidermal growth factor receptor tyrosine kinase inhibitors modulate tumor changes that may be reflected in the alteration of serum proteins. Study objectives are: * To establish...
Detailed Description
Background: Although some success has been achieved in identifying Epidermal growth factor receptor (EGFR) mutations as a molecular predictive marker of response in patients with non-small cell lung ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Any patient with NSCLC receiving erlotinib or gefitinib.
- Patients with unexpected and/or severe treatment related toxicity whilst receiving EGFR TKI.
- Age ≥ 18 years
- Written informed consent.
Exclusion
Key Trial Info
Start Date :
February 1 2006
Trial Type :
OBSERVATIONAL
End Date :
April 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00717847
Start Date
February 1 2006
End Date
April 1 2013
Last Update
December 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National University Hospital
Singapore, Singapore